# Novo Nordisk Stock Drops 7% After Growth Plan Fails to Ease Competition Fears

> Novo Nordisk's stock falls 7% as its post-Wegovy growth plan fails to reassure investors about competition risks
- Title: Novo Nordisk Stock Drops 7% After Growth Plan Fails to Ease…
- Summary: Novo Nordisk's stock falls 7% as its post-Wegovy growth plan fails to reassure investors about competition risks Novo Nordisk's stock dropped 7% after its…
- Keywords: novo nordisk, wegovy, ozempic, glp-1, elijilly, viking therapeutics, nfl, stock market, patent cliff, obesity drugs, capital markets day, semaglutide
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/09/21/novo-nordisk-falls-7-as-post-wegovy-growth-plan-fails-to-ease-competition-fears-eli-lilly-slips-viking-therapeutics-edges-higher
- Author: David Moadel
- Published: 2026-09-21T13:45:22+00:00
- Read time: 1 min
- Topics: novo nordisk, wegovy, ozempic, glp-1, elijilly, viking therapeutics, nfl, stock market, patent cliff, obesity drugs, capital markets day, semaglutide
## Novo Nordisk stock drops
Novo Nordisk stock fell 7% to $40.26 after its capital markets day strategy failed to ease competition fears.
## Eli Lilly stock slips
Eli Lilly stock dropped 0.7% to $1,145.04, showing minimal reaction to Novo Nordisk's market move.
## Viking Therapeutics rises
Viking Therapeutics stock climbed 1% to $29.41 as investors shifted focus to its obesity pipeline.
## Patent cliff looms
Novo Nordisk faces a patent cliff for semaglutide in 2032, threatening its obesity market dominance.
## Growth plan misses
Novo Nordisk's growth plan targets five multi-blockbuster drugs by 2030 but falls short of investor expectations.
## Peer average growth
Investors expect Novo Nordisk's growth to match industry peers, compressing its stock valuation.
## Market reaction
Health care sector ETFs dipped slightly while broader markets rose, indicating a company-specific move.
## Key takeaway

Novo Nordisk's stock dropped 7% after its growth plan failed to ease investor concerns about competition from rivals